vroom, vroom

Forget flying cars — this Houston innovator wants to get flying motorcycles off the ground

A Houston entrepreneur and investor is bullish on bringing flying motorcycles to existence. Courtesy of Aviator Cycles

When it comes to flying cars, Jeff Chimenti wants to give Elon Musk a run for his money — even though Musk, famously, has a lot of that.

But Chimenti is confident that his startup, Aviator Cycles, might be one of the first to get a vehicle off the ground and up into consumer markets. That's because he's not focusing on cars at all — the prototype, unveiled at a recent promotional event in the Woodlands, is a critical propulsion system for what Chimenti calls a personal air vehicle, or PAV.

The PAVs that Aviator Cycles plans to make are more like motorcycles or four-wheelers and intended for recreational use — but the high-tech system could change how other designers make flying vehicles.

"All of this is really happening," says Chimenti, a Houston-based investor and chief visionary officer and co-founder for the startup. "We're pushing it forward."

And, hopefully, upward. Aviator Cycles's first PAV doesn't fly yet, but smaller models have, and Chimenti expects to see a successful launch within one year. The company is making PAVs because there's a lot of red tape around making cars — traffic systems will need to be redrafted.

So for now, the unique propulsion system, which has come a long way since co-founder Jesse Marcel made his first patent on it before the company was even made, is being fastened to the Aerorunner GSX, a sports vehicle that will flutter from about four feet off the ground for safety.

Aviator Cycles plans to start taking reservations for these in the next six months. But Marcel says that his proprietary propulsion system will eventually make its way to other companies and vehicles; Audi, Porsche and Boeing, for example, have announced flying car projects in recent years.

All this innovation is part of a push toward alternative transportation, but it feels like a resurgent space race — just a little lower this time. Aviator Cycles, based in Spokane, Washington, isn't the only manufacturer. In 2018, California-based Hoversurf announced a hoverbike with a set of helicopter blades. It was supposed to ship out earlier this year for $150,000. Across the world — in Britain and Israel, for example — companies are developing bikes to compete in a brand-new flying vehicle market.

"Everybody that designs is great, but they're ultimately going to have to use our propulsion system," says Chimenti.

A new kind of 4x4 might fly, literally, in the Pacific Northwest, where the culture is all hiking and being outside. Texans, though, tend to have a better relationship with their air-conditioners than the great outdoors. Houston, especially, is mostly the urban sprawl of twisting highways — the same unregulatable stretch of concrete that Chimenti has avoided making vehicles for.

But Chimenti is optimistic about the potential for Space City. Last October, the Houston City Council gave $18.8 million to develop the Houston Spaceport, a kind of "mission control" for the future of commercial alternative transportation. Near Ellington Airport, the site has launch pads and lab space — but, maybe most excitingly for people like Chimenti, it has a tech incubator for developers to design and test their equipment.

Houston, then, has a historical stake in how we explore the space above our heads — and what's left for the regular person to explore is closer, below the stratosphere. If Houston has already been instrumental in getting all the way up there, then some light hovering will be nothing. When it comes to flying motocross, Chimenti says, Houston won't have a problem.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News